Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin

@article{Shah2012BenchTB,
  title={Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin},
  author={Dhaval K Shah and Nahor Haddish-Berhane and Alison M. Betts},
  journal={Journal of Pharmacokinetics and Pharmacodynamics},
  year={2012},
  volume={39},
  pages={643-659}
}
To build a multiscale mechanism based pharmacokinetic–pharmacodynamic (PK/PD) model for antibody drug conjugates (ADCs), using brentuximab-vedotin as an example, for preclinical to clinical translation of ADC efficacy. Brentuximab-vedotin experimental data, collected from diverse publications, were employed in the following steps to build and validate the model: (1) characterization of ADC and payload PK at the cellular level, (2) characterization of payload PK in plasma and tumor tissue of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 44 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 36 references

A PK/PD modeling and sim- ulation approach to predict clinical efficacy of antibody drug conjugates from mouse xenograft data

  • N Haddish-Berhane, DK Shah, +5 authors G Hans-Peter
  • J Pharmacokinet Phar- macodyn (manuscript in…
  • 2012
Highly Influential
4 Excerpts

Antibody–Auristatin conjugates for cancer: antibody and drug pharmacokinetics and disposition. Paper pre- sented at the AAPS national biotechnology conference

  • SC Alley
  • San Francisco,
  • 2010
Highly Influential
4 Excerpts

Biomarkers and biomeasures: key enablers for pharmacokinetic–pharmacodynamic modeling in drug discovery and development

  • BM Agoram, PH van der Graaf
  • Bioanalysis
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…